Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 1/20 | 0.45 |
| ▸ | TRPV3 | Q8NET8 | 1/20 | 0.45 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.43 |
| ▸ | MAPT | P10636 | 1/20 | 0.43 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.43 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.43 |
| ▸ | CYP11B1 | P15538 | 1/20 | 0.42 |
| ▸ | CYP11B2 | P19099 | 1/20 | 0.42 |
| ▸ | NUDT1 | P36639 | 1/20 | 0.42 |
| ▸ | ALOX5 | P09917 | 1/20 | 0.42 |
| ▸ | PKM | P14618 | 1/20 | 0.41 |
| ▸ | GRM5 | P41594 | 1/20 | 0.41 |
| ▸ | MAOB | P27338 | 1/20 | 0.41 |
| ▸ | LMNA | P02545 | 1/20 | 0.40 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.40 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.40 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.40 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.40 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.40 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2524154 | 0.88 | L3MBTL1 (0.52) | TSHRTRPV3L3MBTL1MAPTMAPK1 | |
| SCHEMBL1680857 | 0.86 | MAOB (0.50) | MAOB | |
| SCHEMBL17696415 | 0.84 | MAOB (0.45) | TSHRL3MBTL1MAPK1TDP1CYP11B1 | |
| SCHEMBL1712449 | 0.84 | CYP11B1 (0.40) | TRPV3CYP11B1CYP11B2GRM5PTGS1 | |
| SCHEMBL20129054 | 0.82 | TSHR (0.44) | TSHRL3MBTL1TDP1MAOB | |
| SCHEMBL20233737 | 0.82 | TSHR (0.42) | TSHRL3MBTL1MAPTMAPK1TDP1 | |
| SCHEMBL16093384 | 0.82 | SENP8 (0.39) | CYP11B1CYP11B2GRM5MAOB | |
| SCHEMBL5183 | 0.81 | HTR7 (0.51) | TSHRTRPV3L3MBTL1MAPTMAPK1 | |
| SCHEMBL29574709 | 0.81 | HTR7 (0.51) | TSHRTRPV3L3MBTL1MAPTMAPK1 | |
| SCHEMBL509264 | 0.80 | MAOA (0.48) | L3MBTL1TDP1CYP11B1CYP11B2MAOB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 52 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250388605-A1 | HETEROBIFUNCTIONAL COMPOUNDS AND METHODS OF TREATING DISEASE | HALDA THERAPEUTICS OPCO INC (US) | 2025-12-25 | — | — | US | disclosed |
| WO-2024054956-A1 | HETEROBIFUNCTIONAL COMPOUNDS AND METHODS OF TREATING DISEASE | HALDA THERAPEUTICS OPCO, INC. (US) | 2024-03-14 | — | — | WO | disclosed |
| WO-2024054956-A1 | HETEROBIFUNCTIONAL COMPOUNDS AND METHODS OF TREATING DISEASE | HALDA THERAPEUTICS OPCO, INC. (US) | 2024-03-14 | — | — | WO | disclosed |
| US-11247990-B1 | Bicyclic fused pyridine compounds as inhibitors of TAM kinases | ARRAY BIOPHARMA INC (US) | 2022-02-15 | — | — | US | disclosed |
| WO-2019113190-A1 | BICYCLIC FUSED PYRIDINE COMPOUNDS AS INHIBITORS OF TAM KINASES | ARRAY BIOPHARMA INC. (US) | 2019-06-13 | — | — | WO | disclosed |
| US-10286086-B2 | Alternative nucleic acid molecules and uses thereof | MODERNATX, INC. (US) | 2019-05-14 | — | — | US | disclosed |
| US-10150752-B2 | Substituted triazole derivatives as oxytocin antagonists | IXCHELSIS LIMITED (GB) | 2018-12-11 | — | — | US | disclosed |
| US-20170136131-A1 | ALTERNATIVE NUCLEIC ACID MOLECULES AND USES THEREOF | Modema Therapeutics, Inc. (US) | 2017-05-18 | — | — | US | disclosed |
| US-20170114040-A1 | SUBSTITUTED TRIAZOLE DERIVATIVES AS OXYTOCIN ANTAGONISTS | PFIZER LIMITED (GB) | 2017-04-27 | — | — | US | disclosed |
| US-20170114040-A1 | SUBSTITUTED TRIAZOLE DERIVATIVES AS OXYTOCIN ANTAGONISTS | PFIZER LIMITED (GB) | 2017-04-27 | — | — | US | disclosed |
| US-20090253674-A1 | Substituted Triazole Derivatives As Oxytocin Antagonists | PFIZER INC | 2009-10-08 | — | — | US | disclosed |
| US-20090253674-A1 | Substituted Triazole Derivatives As Oxytocin Antagonists | PFIZER INC | 2009-10-08 | — | — | US | disclosed |
| US-7557131-B2 | Substituted triazole derivatives as oxytocin antagonists | PFIZER INC (US) | 2009-07-07 | — | — | US | disclosed |
| US-7557131-B2 | Substituted triazole derivatives as oxytocin antagonists | PFIZER INC (US) | 2009-07-07 | — | — | US | disclosed |
| US-7557131-B2 | Substituted triazole derivatives as oxytocin antagonists | PFIZER INC (US) | 2009-07-07 | — | — | US | disclosed |
| EP-1841758-A1 | SUBSTITUTED TRIAZOLE DERIVATIVES AS OXYTOCIN ANTAGONISTS | Pfizer Limited (GB) | 2007-10-10 | — | — | EP | disclosed |
| WO-2006077496-A1 | SUBSTITUTED TRIAZOLE DERIVATIVES AS OXYTOCIN ANTAGONISTS | PFIZER LIMITED (GB) | 2006-07-27 | — | — | WO | disclosed |
| US-20060160786-A1 | Substituted triazole derivatives as oxytocin antagonists | PFIZER INC | 2006-07-20 | — | — | US | disclosed |
| US-20060160786-A1 | Substituted triazole derivatives as oxytocin antagonists | PFIZER INC | 2006-07-20 | — | — | US | disclosed |
| US-20060160786-A1 | Substituted triazole derivatives as oxytocin antagonists | PFIZER INC | 2006-07-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250388605-A1 | HETEROBIFUNCTIONAL COMPOUNDS AND METHODS OF TREATING DISEASE | BRD4, BRDT, BICRA | TSHR 670/4885TRPV3 1432/4885L3MBTL1 1370/4885 |
| US-20170114040-A1 | SUBSTITUTED TRIAZOLE DERIVATIVES AS OXYTOCIN ANTAGONISTS | OXTR, AVPR1B, GNRHR | TSHR 247/4885TRPV3 452/4885L3MBTL1 4468/4885 |
| US-20170136131-A1 | ALTERNATIVE NUCLEIC ACID MOLECULES AND USES THEREOF | NSUN2, RNGTT, NSUN3 | TSHR 3169/4885TRPV3 4032/4885L3MBTL1 279/4885 |
| US-20060160786-A1 | Substituted triazole derivatives as oxytocin antagonists | OXTR, AVPR1B, GNRHR | TSHR 247/4885TRPV3 452/4885L3MBTL1 4468/4885 |
| US-10286086-B2 | Alternative nucleic acid molecules and uses thereof | NSUN2, RNGTT, NSUN3 | TSHR 3169/4885TRPV3 4032/4885L3MBTL1 279/4885 |
| US-11247990-B1 | Bicyclic fused pyridine compounds as inhibitors of TAM kinases | MAP3K1, MAP3K3, MAP3K2 | TSHR 724/4885TRPV3 3296/4885L3MBTL1 2152/4885 |
| US-20090253674-A1 | Substituted Triazole Derivatives As Oxytocin Antagonists | OXTR, AVPR1B, GNRHR | TSHR 247/4885TRPV3 452/4885L3MBTL1 4468/4885 |
| US-10150752-B2 | Substituted triazole derivatives as oxytocin antagonists | OXTR, AVPR1B, GNRHR | TSHR 247/4885TRPV3 452/4885L3MBTL1 4468/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.